GlassScriptPhysician profile
Eran Matalon
NPI 1073656815
$2,817.46
in general payments reported to CMS, 2019-2025
29 companies · $91.27 in 2025
The $91.27 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,369 · 2020: $488 · 2021: $59.83 · 2022: $237 · 2023: $410 · 2024: $163 · 2025: $91.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $664.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $816.64 | 2019-2025 | |
| Amgen INC. | $350.30 | 2019-2022 | |
| Glaxosmithkline, LLC. | $253.65 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $212.12 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $192.38 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $147.74 | 2019 | |
| Avanir Pharmaceuticals, INC. | $128.81 | 2019-2020 | |
| Edwards Lifesciences Corporation | $87.02 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $85.48 | 2019-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $55.54 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $54.67 | 2019-2020 | |
| Medtronic, INC. | $48.68 | 2023 | Linq II |
| Novo Nordisk INC | $40.28 | 2019 | |
| Allergan, INC. | $40.26 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $37.15 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $32.29 | 2019 | |
| Viiv Healthcare Company | $27.04 | 2024 | Apretude |
| Horizon Therapeutics Plc | $25.45 | 2019 | |
| Boston Scientific Corporation | $22.96 | 2023 | Watchman Access System |
| Biohaven Pharmaceutical Holding Company LTD. | $22.88 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.97 | 2019 | |
| Sanofi Pasteur INC. | $19.17 | 2020 | |
| Astellas Pharma US INC | $17.62 | 2019 | |
| Merck Sharp & Dohme LLC | $14.35 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.24 | 2019 | |
| Neurocrine Biosciences, INC. | $14.21 | 2020 | |
| Smith+Nephew, INC. | $12.91 | 2019 | |
| Amarin Pharma, INC. | $12.64 | 2019 | |
| Therapeuticsmd, INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eran Matalon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.